Rivastigmine, another FDA-approved acetylcholinesterase inhibitor for neurological symptoms in Alzheimer’s and Parkinson’s disease, triggers cholinergic hyperactivation-related adverse effects, like nausea and vomiting (Varadharajan et al., 2023). The gene discussed is ACHE; the disease is Parkinson disease.